Detalles de la búsqueda
1.
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Ann Rheum Dis
; 77(2): 234-240, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29042358
2.
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 76(1): 58-64, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26318384
3.
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Rheumatology (Oxford)
; 56(10): 1771-1779, 2017 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28957563
4.
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Arthritis Rheumatol
; 70(1): 40-48, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28950421
Resultados
1 -
4
de 4
1
Próxima >
>>